Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan. 20, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsored research agree... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2022 Category: Pharmaceuticals Source Type: news

FAPI-PET may improve diagnosis of gastric cancer
Hybrid PET/MR imaging with an experimental gallium-68-labeled fibroblast activatio...Read more on AuntMinnie.comRelated Reading: Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging New tracer bests FDG for diagnosing liver cancer Sofie receives nod to start trial for PET tracer PET imaging lays foundation for new cancer therapies PET tracer shows promise for diagnosing breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 19, 2022 Category: Radiology Source Type: news

How cutting doses of cancer therapy can reduce side-effects... but be just as effective
The search for smarter - better, shorter and less toxic or damaging - cancer treatments, with better outcomes, such as TAD is now a holy grail of cancer research. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2022 Category: Consumer Health News Source Type: news

Moderna strikes $80M deal with Carisma Therapeutics to collaborate on cancer treatments
Moderna has entered into a research collaboration with Carisma Therapeutics with an upfront payment of $45 million for the Philadelphia cell therapy developer. Cambridge-based Moderna (NASDAQ: MRNA) will also invest $35 million in Carisma in the form of a convertible note, and in return get options for up to 12 targets for potential cancer therapies. Under the partnership, the two companies will work together to discover, develop and commercialize poten tial cancer treatments. The treatments will… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 10, 2022 Category: American Health Authors: John George Source Type: news

Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging
PET/CT imaging with an experimental gallium-68-based (Ga-68) radiotracer tha...Read more on AuntMinnie.comRelated Reading: New tracer bests FDG for diagnosing liver cancer PET imaging lays foundation for new cancer therapies PET tracer shows promise for diagnosing breast cancer New PET radiotracer more effective at detecting cancer Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 10, 2022 Category: Radiology Source Type: news

Carisma Therapeutics to get $80M in cash and investment through new deal with Moderna
Philadelphia cell therapy developer Carisma Therapeutics has entered into a research collaboration with Moderna that includes Carisma receiving an upfront payment of $45 million. Moderna (NASDAQ: MRNA) will also invest $35 million in Carisma in the form of a convertible note, and in return get options for up to 12 targets for potential cancer therapies. Under the partnership, the two companies will work together to discover, develop and commercialize potential cancer trea tments. The treatments… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 10, 2022 Category: Health Management Authors: John George Source Type: news

Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT(TM) in Malignant Skin and Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
JERUSALEM, Jan. 10, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center ... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2022 Category: Pharmaceuticals Source Type: news

Telix, Olivia Newton-John Cancer Research Institute to collaborate
Telix Pharmaceuticals plans to collaborate with the Olivia Newton-John Cance...Read more on AuntMinnie.comRelated Reading: Telix secures FDA clearance for prostate cancer PET imaging agent Telix applauds NCCN radiotracer update Telix, Kettering to research PSMA radiotracer Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 4, 2022 Category: Radiology Source Type: news

Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head and Neck Cancer
JERUSALEM, Jan. 3, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 3, 2022 Category: Pharmaceuticals Source Type: news

Telix secures FDA clearance for prostate cancer PET imaging agent
Telix Pharmaceuticals has secured clearance from the U.S. Food and Drug Administratio...Read more on AuntMinnie.comRelated Reading: Telix applauds NCCN radiotracer update Telix, Kettering to research PSMA radiotracer Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2021 Category: Radiology Source Type: news

Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer
Patients with metastatic disease receiving aromatase inhibitor plus palbociclib and with a rising ESR1 mutation may benefit from early switch to fulvestrant plus palbociclib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Immatics inks $920M licensing deal with Bristol Myers Squibb
Immatics, which develops a pipeline of cancer therapies, has an administrative office and a research laboratory in Houston. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 14, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news

Cellogen to bring next-gen cancer therapy to India
"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to offer IGIB's expertise in genome manipulation towards translational efforts in this area", said Dr. Anurag Agrawal, Director, CSIR-IGIB at the inking of the agreement with Cellogen Therapeutics. (Source: The Economic Times)
Source: The Economic Times - December 13, 2021 Category: Consumer Health News Source Type: news

No Benefit to Adding Palbociclib to Early Breast Cancer Therapy No Benefit to Adding Palbociclib to Early Breast Cancer Therapy
A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New tracer bests FDG for diagnosing liver cancer
PET/CT imaging of hepatocellular carcinoma with an experimental gallium-68-base...Read more on AuntMinnie.comRelated Reading: Sofie receives nod to start trial for PET tracer PET imaging lays foundation for new cancer therapies PET tracer shows promise for diagnosing breast cancer Sofie submits IND application for pancreatic PET agent New PET radiotracer more effective at detecting cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2021 Category: Radiology Source Type: news

Advancements Series to Explore Breakthroughs in Biopharmaceutical...
Get an inside look at the next generation of medicines for cancer therapy.(PRWeb December 09, 2021)Read the full story at https://www.prweb.com/releases/advancements_series_to_explore_breakthroughs_in_biopharmaceutical_technology/prweb18382243.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2021 Category: Pharmaceuticals Source Type: news

Antimicrobial Resistance Calls for Brainpower of a Space Agency and Campaigning Zeal of an NGO
This article is republished from The Conversation under a Creative Commons license. Read the original article. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - November 17, 2021 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Source Type: news

Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
BERKELEY, Calif., Nov. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the ... Biopharmaceuticals, Oncology, Personnel Actym Therapeutics, S. Typhimurium-Attenuated Cancer Therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 11, 2021 Category: Pharmaceuticals Source Type: news

PET imaging lays foundation for new cancer therapies
PET imaging of cancer patients with an experimental gallium-68 (Ga-68) trace...Read more on AuntMinnie.comRelated Reading: PET tracer shows promise for diagnosing breast cancer Sofie submits IND application for pancreatic PET agent New PET radiotracer more effective at detecting cancer PET detects activity in early atherosclerosis Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 8, 2021 Category: Radiology Source Type: news

Changing Cancer Care, So Patients No Longer Feel Like a Number
“Having cancer is terrifying. It’s scary. And going to the hospital—I really felt like a number,” says Marc Hulett, who was diagnosed with prostate cancer in 2004. Hulett had surgery to remove his prostate and has been on hormone therapy for 17 years. Every three months, he gets a blood test to monitor his progress, but he no longer feels like a number. He drives from his home in Palm Springs, Calif., to Los Angeles—which can take up to six hours—to see his oncologist, Dr. David Agus, at the Ellison Institute for Transformative Medicine. As the name suggests, the Institute isn’t ju...
Source: TIME: Health - November 3, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news

Inovio, AstraZeneca terminate cancer vaccine partnership
MedImmune Ltd., the global biologics research and development arm of AstraZeneca (NYSE: AZN), is terminating a cancer therapy partnership it has with Inovio Pharmaceuticals. The partnership, formed in 2015, gave MedImmune of Gaithersburg, Maryland, exclusive rights to Inovio's experimental DNA-based cancer vaccine, known as INO-3112, for cancers caused by human papillomavirus (HPV) types 16 and 18. MedImmune renamed the new drug candidate as MED10457 after acquirin g its exclusive rights. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Accuray touts ASTRO results in breast cancer therapy
Accuray is highlighting clinical results that suggest that early-stage breas...Read more on AuntMinnie.comRelated Reading: Accuray reports revenue gains for Q1 Accuray to introduce Volo Ultra at ASTRO 2021 Accuray inks collaboration with C-RAD Accuray promotes prostate cancer research at ESTRO 2021 Accuray lands Radixact install in India (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2021 Category: Radiology Source Type: news

Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera Therapeutics stock plunged by more than 70% Tuesday after the Malvern biopharmaceutical firm said its lead experimental cancer therapy failed to meet its primary endpoint in late-stage clinical testing. The new drug candidate, called GC4419, is under development as a treatment for severe oral mucositis in patients with locally advanced head and neck cancer undergoing radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of severe oral mucositis, a condition… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2021 Category: Biotechnology Authors: John George Source Type: news

Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors. Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998. "Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 18, 2021 Category: American Health Authors: Rick Morgan Source Type: news

Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors. Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998. "Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2021 Category: Biotechnology Authors: Rick Morgan Source Type: news

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIR... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2021 Category: Pharmaceuticals Source Type: news

Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT ... Devices, Oncology Alpha Tau Medical, Alpha DaRT, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2021 Category: Pharmaceuticals Source Type: news

Medical College of Wisconsin hires CannonDesign for $100M cancer research center project
The Medical College of Wisconsin hired global firm CannonDesign for what it called Milwaukee ’s first research center dedicated to cancer therapies and treatments. That MCW Cancer Research Building was first announced in 2019 as an about $100 million, 150,000-square-foot facility. It would expand on the cancer research the Medical College is already doing at the Milwaukee Regional Medic al Center in Wauwatosa. Design work is to start this fall and will last into 2022, according to a Tuesday announcement… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 28, 2021 Category: American Health Authors: Sean Ryan Source Type: news

Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
SAN DIEGO, Sept. 22, 2021 -- (Healthcare Sales & Marketing Network) -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, ... Biopharmaceuticals, Oncology Kintara Therapeutics, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 22, 2021 Category: Pharmaceuticals Source Type: news

Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches  Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs.   Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abex...
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news

Telix applauds NCCN radiotracer update
Injection kit developer Telix applauded the National Comprehensive Cancer Network'...Read more on AuntMinnie.comRelated Reading: Telix, Kettering to research PSMA radiotracer Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2021 Category: Radiology Source Type: news

Gilead Sciences considered Atlanta, Durham before selecting Raleigh for 275 jobs
The maker of breakthrough HIV, hepatitis C and cancer therapies — as well as the Covid drug remdesivir — snagged nearly $10 million reimbursement incentive and more than $357,000 in community college training incentives from North Carolina. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 16, 2021 Category: American Health Authors: Lauren Ohnesorge Source Type: news

Cell therapy partnership between Bay Area biotechs offers hope to cancer patients
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Lauren Lawley Head Source Type: news

Heating Up CAR T Cells for Cancer Therapy
Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells. (Source: The Scientist)
Source: The Scientist - September 10, 2021 Category: Science Tags: Sponsored Article Source Type: news

B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
To Downsize Systems and Spread High-precision Irradiation Technology TOKYO, Sept. 9, 2021 -- (Healthcare Sales & Marketing Network) -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at i... Devices, Oncology, Radiology B dot Medical, proton therapy, compact proton cancer therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 9, 2021 Category: Pharmaceuticals Source Type: news

Telix, Kettering to research PSMA radiotracer
Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix'...Read more on AuntMinnie.comRelated Reading: Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 8, 2021 Category: Radiology Source Type: news

Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
David Miklos discusses recent advances in bispecific CAR-T therapy development. (Source: The Scientist)
Source: The Scientist - September 7, 2021 Category: Science Tags: Sponsored Webinars Source Type: news

RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
510(k) Device May Improve Targeted Delivery of Chemotherapy LOS ALTOS, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announc... Devices, Drug Delivery, Oncology, FDA RenovoRx, RenovoCath Delivery System, RenovoGem, RenovoTAMP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news

CV Safety Study of Cancer Therapy Attracts Attention CV Safety Study of Cancer Therapy Attracts Attention
Although the first global trial to compare the cardiovascular (CV) safety of two therapies for prostate cancer proved inconclusive, it was"a model for interdisciplinary collaboration" says investigator.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 31, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Review Eyes Nail Toxicities Related to Targeted Cancer Therapy Review Eyes Nail Toxicities Related to Targeted Cancer Therapy
The investigators found that paronychia and periungual pyogenic granulomas were the most common nail unit toxicities caused by targeted therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 24, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Lightpoint, Telix ink collaboration agreement
Luminescence imaging technology developer Lightpoint Medical has signed a collaboratio...Read more on AuntMinnie.comRelated Reading: Telix works with Merck on cancer therapies Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply Lightpoint announces new CEO Lightpoint gets CE Mark for Sensei device Lightpoint licenses molecular imaging technology (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 23, 2021 Category: Radiology Source Type: news

Telix works with Merck on cancer therapies
Telix Pharmaceuticals is entering into a collaboration with Merck for researc...Read more on AuntMinnie.comRelated Reading: Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply ARTMS, Telix produce PSMA-11 in cyclotron Telix files NDA for prostate cancer PET imaging agent RefleXion, Telix partner on high-risk cancer treatments (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 20, 2021 Category: Radiology Source Type: news

Navrogen raises $3M in venture capital financing to advance cancer therapy platform
The four-year-old company also converted more than $3 million in notes into equity. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 16, 2021 Category: Biotechnology Authors: John George Source Type: news

Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Cancer Therapy and Myocardial Dysfunction: 5 Things to Know Cancer Therapy and Myocardial Dysfunction: 5 Things to Know
An expert overview of some key aspects to preventing, monitoring, and managing cardiac dysfunction related to cancer therapy.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 26, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Novel imaging agent identifies biomarker for iron-targeted cancer therapies
(Society of Nuclear Medicine and Molecular Imaging) A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Cancer: Information theory to fight resistance to treatments
(Universit é de Gen è ve) A major challenge in cancer therapy is the adaptive response of cancer cells to targeted therapies. Although this adaptive response is theoretically reversible, such a reversal is hampered by numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. A team (UNIGE/HUG) has used information theory, in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2021 Category: International Medicine & Public Health Source Type: news

Scientists provide new insight on how to stop transcription of cancer cells
(University of California - Los Angeles Health Sciences) Findings could help pave the way for cancer therapies that target TAF12, potentially stopping transcription in cancer cells and helping decrease the growth of cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Homing Technology Delivers Therapy to Cancerous Bone
A clever approach to modifying already existing cancer therapies may be a game changer for treating metastatic breast cancer. (Source: The Scientist)
Source: The Scientist - July 19, 2021 Category: Science Tags: Sponsored Article Source Type: news